Faron Pharmaceuticals - Innovative medical solutions (Part 2)

It’s a bit gut-wrenching how poorly this offering was handled. The share price was €1.92 when the news broke. With smarter marketing, this could have been handled at, say, one euro per share. Now, after costs, only ~40% of that remains, if even that. At the same time, the company’s fixed costs are sky-high; I doubt the management will be going hungry even if the company goes bankrupt.

It remained a bit unclear to me whether HCM is being paid out or not? Can someone in the know clarify? Or are their pockets just getting even fatter from this?

6 Likes